Lynparza

AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
BioPharma Dive
AstraZeneca
Merck
cediranib
ovarian cancer
clinical trials
Lynparza
Flag link:
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
Flag link:
FDA Approves New Pancreatic Treatment Found To Double Time Patients Live Without Disease Progression
FDA Approves New Pancreatic Treatment Found To Double Time Patients Live Without Disease Progression
Forbes
FDA
Lynparza
AstraZeneca
pancreatic cancer
Flag link:
FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer
FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer
BioSpace
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
Flag link:
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
advisory panels
Flag link:
Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide
Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
BRCA-mutated pancreatic cancer
pancreatic cancer
Flag link:
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula
Flag link:
AstraZeneca strengthens lead in PARP drug class
AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
Flag link:
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
Flag link:
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula
Flag link:
ESMO 2019 preview – PARPs on parade
ESMO 2019 preview – PARPs on parade
EP Vantage
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
Flag link:
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
Pharmaforum
AstraZeneca
Merck
Lynparza
clinical trials
advanced ovarian cancer
ovarian cancer
Calquence
Flag link:
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
Yahoo/Benzinga
AstraZeneca
Clovis Oncology
prostate cancer
Lynparza
Flag link:
AstraZeneca cancer drugs build as primary care shrinks
AstraZeneca cancer drugs build as primary care shrinks
Biopharma Dive
AstraZeneca
cancer
oncology
primary care
Tagrisso
Symbicort
Lynparza
Flag link:
Clovis investors feel more Lynparza pressure
Clovis investors feel more Lynparza pressure
EP Vantage
prostate cancer
Lynparza
Rubraca
Clovis Oncology
AstraZeneca
Merck
Flag link:
AstraZeneca, Merck herald PhIII prostate cancer win for Lynparza — overtaking Clovis, J&J in PARP race
AstraZeneca, Merck herald PhIII prostate cancer win for Lynparza — overtaking Clovis, J&J in PARP race
Endpoints
Lynparza
AstraZeenca
Merck
prostate cancer
clinical trials
Flag link:
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
Yahoo/Reuters
AstraZeneca
Lynparza
ovarian cancer
Europe
Flag link:
ASCO 2019 day one
ASCO 2019 day one
Pharmaforum
ASCO 2019
JNJ
Erleada
AstraZeneca
Merck
Lynparza
prostate cancer
Flag link:
Lynparza on cusp of EU approval for advanced ovarian cancer
Lynparza on cusp of EU approval for advanced ovarian cancer
Pharmaforum
AstraZeneca
Lynparza
Europe
CHMP
ovarian cancer
Flag link:
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
Pharmaforum
AstraZeneca
Merck
Lynparza
BRCA-mutant breast cancer
Europe
breast cancer
Flag link:

Pages